Market Overview

UPDATE: Morgan Stanley Downgrades Mylan to Equal-Weight Following Outperformance

Share:
Related MYL
Benzinga's Weekend M&A Chatter
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
Mylan (Investor's Business Daily)

Morgan Stanley downgraded Mylan Inc. (NASDAQ: MYL) from Overweight to Equal-weight and removed the price target of $27.00.

Morgan Stanley commented, "Mylan is above our previous $27 price target, and we are downgrading from OW to EW on a more balanced risk-reward. The market now appears to be pricing in better growth prospects in EMEA and the potential for accretive M&A."

Mylan closed at $27.91 on Monday.

Latest Ratings for MYL

DateFirmActionFromTo
Aug 2015Standpoint ResearchInitiates Coverage onBuy
Jul 2015Cowen & CompanyDowngradesOutperformMarket Perform
Jun 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (MYL)

Get Benzinga's Newsletters